• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Astria Therapeutics, Inc.

    < Previous 1 2 3 Next >
    Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming Global Angioedema Forum
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming Bradykinin Symposium
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Tickers ATXS
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.